Search results for "Antinuclear"

showing 4 items of 34 documents

Optical biosensor-based characterization of anti-double-stranded DNA monoclonal antibodies as possible new standards for laboratory tests.

2009

The serum determination of circulating anti-double-stranded (ds)DNA autoantibodies is a routine measure for the laboratory diagnosis of systemic lupus erythematosus. Since available assays differ substantially and no feasible calibrator is available, the aim of this study was to evaluate a recently introduced surface plasmon resonance (SPR) biosensor chip for binding studies between dsDNA and anti-dsDNA autoantibodies and to demonstrate its usefulness for the characterization of new monoclonal antibody (mAb) standards and standardization of assays. We characterized two human and one murine monoclonal anti-dsDNA antibodies by measuring the kinetic on- and off-rates using the biosensor and ca…

medicine.drug_classBiomedical EngineeringBiophysicsElectrophoretic Mobility Shift AssayMonoclonal antibodyBinding Competitivechemistry.chemical_compoundMiceElectrochemistrymedicineAnimalsHumansLupus Erythematosus SystemicAviditySurface plasmon resonancebiologyChemistryAntibodies MonoclonalGeneral MedicineDNASurface Plasmon ResonanceMolecular biologyDissociation constantKineticsBiochemistryAntibodies AntinuclearMonoclonalbiology.proteinBinding Sites AntibodyAntibodyBiosensorDNABiotechnologyBiosensorsbioelectronics
researchProduct

Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observation…

2022

AbstractThe detection of antinuclear autoantibody (ANA) is dependent on many factors and varies between the populations. The aim of the study was first to assess the prevalence of ANA in the Polish adult population depending on age, sex and the cutoff threshold used for the results obtained. Second, we estimated the occurrence of individual types of ANA-staining patterns. We tested 1731 patient samples using commercially available IIFA using two cutoff thresholds of 1:100 and 1:160. We found ANA in 260 participants (15.0%), but the percentage of positive results strongly depended on the cutoff level. For a cutoff threshold 1:100, the positive population was 19.5% and for the 1:160 cutoff th…

musculoskeletal diseasesAdultMaleRMAnti-nuclear antibodyCross-sectional studyIndirect immunofluorescence assayImmunologyPopulationAdult populationPolish populationObservational ResearchAutoimmune DiseasesAgeSex FactorsRheumatologyCutof thresholdPrevalenceImmunology and AllergyCutoffMedicineHumanseducationskin and connective tissue diseasesQH426education.field_of_studybusiness.industryAutoantibodyAge FactorsMiddle AgedQRCutoff thresholdstomatognathic diseasesAntinuclear antibodiesCross-Sectional StudiesIndirect immunofuorescence assayAntibodies AntinuclearQR180Observational studySexFemalePolandbusinessDemographyRheumatology International
researchProduct

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

2020

Introduction We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). Methods ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. Results Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. Discussion Once AIH has been ruled out, the long-term outcomes and survival are un…

musculoskeletal diseasesMalemedicine.medical_specialtyAntibodies Antinuclear; Biopsy; England; Female; Humans; Italy; Longitudinal Studies; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prevalence; Prospective Studies; Survival AnalysisAnti-nuclear antibodyBiopsySettore MED/12 - GASTROENTEROLOGIAAntibodies Antinuclear Biopsy EnglandFemale Humans Italy Longitudinal Studies Male Middle Aged Non-alcoholic Fatty Liver Disease Prevalence Prospective StudiesSurvival AnalysisAutoimmune hepatitisMalignancyGastroenterologyAntibodies03 medical and health sciences0302 clinical medicineimmune system diseasesNon-alcoholic Fatty Liver DiseaseInternal medicineAntinuclearBiopsyNonalcoholic fatty liver diseasemedicineCarcinomaPrevalenceHumansLongitudinal StudiesProspective Studiesskin and connective tissue diseasesProspective cohort studySurvival analysisHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseases3. Good healthstomatognathic diseasesn/aEnglandItaly030220 oncology & carcinogenesisAntibodies Antinuclear030211 gastroenterology & hepatologyFemalebusiness
researchProduct

Real-world experience with obeticholic acid in patients with primary biliary cholangitis

2021

Background & aims Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. Methods Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level. The primary endpoint was the biochemical response according to Poise criteria; the secondary endpoint was the biochemical response according to normal range criteria, defined as normal levels of bilirubin, alkaline phosphatase (ALP), and alanine aminotransfer…

upper limit of normalCirrhosisALTAMAAutoimmunityantinuclear antibodiesULNPBCGastroenterologyUDCASettore MED/12ULN upper limit of normalobeticholic acidaRR adjusted risk ratio.CRFs case record formAST aspartate transferaseClinical endpointGGT gamma-glutamyl transferaseQCprimary biliary cholangitisGastroenterologyUrsodeoxycholic acidANATCCCirrhosisCholestasiTIPSTreatment Completer CohortANA antinuclear antibodiemedicine.medical_specialtyRRUDCA ursodeoxycholic acidTIPS transjugular intrahepatic portosystemic shuntOCACirrhosiALP alkaline phosphataseautoimmune hepatitismedicine.diseasedigestive system diseasesDiscontinuationKeywords: AIH autoimmune hepatitiQC quality controlchemistrygamma-glutamyl transferaserandomised controlled trialelectronic data captureantimitochondrial antibodiesaspartate transferaseAutoimmune hepatitischemistry.chemical_compoundAIHCRFsImmunology and Allergyadjusted risk ratioANA antinuclear antibodiesRR risk ratioOverall cohortALT alanine transferaseAMA antimitochondrial antibodieCholestasisCRFs case record formsObeticholic acidOverlap PBC-AIHursodeoxycholic acidOCA obeticholic acidTolerabilityalkaline phosphataseRCTResearch Articlemedicine.drugcase record formsContext (language use)AMA antimitochondrial antibodiesInternal medicineEDC electronic data capturetransjugular intrahepatic portosystemic shuntInternal MedicinemedicineRCT randomised controlled trialaRR adjusted risk ratioOClcsh:RC799-869quality controlalanine transferaseASTaRRHepatologybusiness.industryAutoimmunity; Cholestasis; Cirrhosis; Overlap PBC-AIHAIH autoimmune hepatitisTCC Treatment Completer CohortPBC primary biliary cholangitiGGTrisk ratioOC Overall cohortALPlcsh:Diseases of the digestive system. GastroenterologyPBC primary biliary cholangitisbusinessEDC
researchProduct